AGTC Announces Agenda for R&D Day on January 28, 2020 in New York - Seite 2

° Paul Castle, diagnosed with XLRP
 

XLRP Indication, Product Construct and Data to Date
° Dr. David G. Birch, PhD, Director of the Rose-Silverthorne Retinal Degeneration Laboratory, Scientific Director at the Retina Foundation of the Southwest, adjunct professor of ophthalmology at the University of Texas Southwestern Medical Center in Dallas, Texas. Member of the ophthalmology scientific advisory board at AGTC
° Dr. Mark Shearman, AGTC Chief Scientific Officer
 

ACHM Patient Perspective
° Rachelle Lin, OD, MS, FAAO, Assistant Professor at Marshall B. Ketchum University and Low Vision Rehabilitation and Acquired Brain Injury clinician at the University Eye Center at Ketchum Health in Anaheim, CA
° Alison Lynch, diagnosed with ACHM
 

ACHM Indication, Product Construct and Data to Date
° Dr. Paul Yang, MD, PhD, Assistant Professor of Ophthalmology at the Casey Eye Institute, Oregon Health & Science University in Portland
° Dr. Mark Shearman, AGTC Chief Scientific Officer
 

AAV Gene Therapy Delivery: Review of Subretinal Injection Procedure
° Andy K. Lauer, MD, Chair of the Department of Ophthalmology at the Casey Eye Institute, Oregon Health & Science University in Portland
 

Corporate Research: Manufacturing Capabilities and Pre-Clinical Programs
° Dr. Dave Knop, AGTC Executive Director, Process Development
° Dr. Mark Shearman, AGTC Chief Scientific Officer

A live audio webcast of the presentation with accompanying slides can be accessible by visiting ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time.

Members of the institutional investment community interested in attending can RSVP by clicking the RSVP link in the Events & Presentations page of the investor section at AGTC.com.

The archived webcast and slide presentation will be available in the Events and Presentations section of the Company's website.

About AGTC
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, in which it has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics; adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS), and other CNS, ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products, including capsids, promoters, and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.